Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Apotex Execs Avoid Criminal Charges Under DOJ Deferred Prosecution Agreement

Executive Summary

While former Sandoz and Heritage execs were charged in the government's generic price-fixing probe, Apotex and its employees will apparently escape such fate if they abide by the terms of DOJ agreement; company admits to fixing price of pravastatin and agrees to pay $24.1m criminal penalty.

You may also be interested in...



Teva Gambles Indictment Is Better Than Pleading Guilty To US Price-Fixing Claims

Teva’s market overhang and legal uncertainty intensifies with DOJ charges it conspired to fix generic drug prices. Five other companies have pled guilty and reached deferred prosecution agreements.

Teva Gambles Indictment Is Better Than Pleading Guilty To Price-Fixing Claims

Teva’s market overhang and legal uncertainty intensifies with DOJ charges it conspired to fix generic drug prices. Five other companies have pled guilty and reached deferred prosecution agreements.

Generic Price-Fixing: Sandoz Employee Notebook Provides Evidence For AGs' Third Suit

Complaint names 26 generic dermatologic drug manufacturers and 10 individual executives as defendants, alleging they engaged in a widespread conspiracy to artificially inflate and manipulate prices. State attorneys general say that structural and personnel changes at the companies fostered and facilitated collusion.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS142158

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel